Device Trial Radar · NCT07690995
Evaluating a New Software (OTOGUIDE) to Help Monitor Electrode Insertion During Cochlear Implant Surgery.
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Aug 18, 2026
Primary completion
Dec 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- MED-EL Elektromedizinische Geräte GmbHNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cochlear implants are a successful treatment for severe hearing loss in both children and adults. The procedure involves placing an electrode array into the cochlea to stimulate the auditory nerve, helping patients to hear. For the best results, it's crucial to place the electrode precisely and gently to avoid damaging delicate structures inside the ear. However, currently, surgeons lack feedback on the insertion status, making it difficult to confirm correct electrode positioning, especially regarding insertion depth, such as angle, frequency, or millimeters. New technologies are being developed to provide feedback during surgery, helping surgeons place the electrode more accurately. One such technology, recently developed by MED-EL, is called OTOGUIDE. This software offers immediate information on the electrode's position and functioning during the operation, aiming to improve surgical precision and hearing outcomes. This clinical investigation aims to evaluate the performance and safety of OTOGUIDE, which assists surgeons during cochlear implant procedures by helping identify the position and angle of electrode contacts placed inside the cochlea. The primary objective is to confirm that OTOGUIDE can accurately detect which electrodes are inserted into the cochlea, with results that are more than 80% consistent with standard CT imaging (either during or after surgery). The secondary objective is to verify that OTOGUIDE can estimate the insertion angle of a specific electrode (C1) with a margin of error smaller than 60 degrees compared to CT imaging. Participants who agree to take part and sign the informed consent form will undergo up to three study visit, which coincides with their scheduled routine cochlear implant surgery visits. During the Surgery Visit intraoperative measurements will be performed using both OTOGUIDE and the MAESTRO system. CT imaging (either during or after surgery, depending on routine clinical practice) will be used to verify the electrode array's position inside the cochlea.
Conditions
- Cochlear Implantation
- Monitoring Electrode Insertion
Interventions
OTOGUIDE softwareDevice
OTOGUIDE performs objective measurements to enable the monitoring of the electrode insertion and the functioning of the electrode. OTOGUIDE guides the users through a workflow-based session to assess the implant status and to define a surgical approach. The users can plan an insertion target and monitor the real-time electrode insertion using an impedance-based method to automatically detect the number of contacts inside the cochlea.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of inserted electrodesTime frame: through study completion, an average of 1 year
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Medizinische Universität Innsbruck
Innsbruck, Tyrol, Austria · Recruiting
Klinikum der Universität München, Campus Großhadern Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde
Munich, Bavaria, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.